TNX-1700

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a patient-focused biotechnology company dedicated to developing impactful treatments for complex, chronic conditions that defy easy answers, including nociplastic pain, immunology/immuno-oncology, and infectious diseases. Its strategy leverages an integrated clinical development engine to advance a diverse pipeline, with key programs like TNX-102 SL for acute stress disorder expected to report Phase 2 topline data in the second half of 2026. The company's mission is to empower patients to live fully through scientific rigor and a deep respect for the patient experience, supported by a leadership team with significant industry expertise.

Therapeutic Areas